Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Q Biomed Inc (QBIO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 24,293
  • Shares Outstanding, K 14,290
  • Annual Sales, $ 0 K
  • Annual Income, $ -14,540 K
  • 36-Month Beta 1.94
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.31
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 12/05/18
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 11/30/18
See More
  • Average Estimate -0.22
  • Number of Estimates 2
  • High Estimate -0.21
  • Low Estimate -0.22
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.02%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.9500 +78.95%
on 12/13/18
2.1900 -22.37%
on 11/15/18
-0.4200 (-19.81%)
since 11/14/18
3-Month
0.9500 +78.95%
on 12/13/18
3.3700 -49.55%
on 10/01/18
-1.1500 (-40.35%)
since 09/14/18
52-Week
0.9500 +78.95%
on 12/13/18
4.6000 -63.04%
on 01/03/18
-2.8100 (-62.31%)
since 12/14/17

Most Recent Stories

More News
Q BioMed Announces Strategic Partnership With SRI International for Formulation and Preclinical Development of QBM-001 for Pediatric Nonverbal Disorder in Autistic Children

NEW YORK , December 12, 2018 /PRNewswire/ --

QBIO : 1.7000 (unch)
Q BioMed Announces Strategic Partnership With SRI International for Formulation and Preclinical Development of QBM-001 for Pediatric Nonverbal Disorder in Autistic Children

Q BioMed Inc. (OTCQB: QBIO), a biotechnology acceleration company, is pleased to announce a collaborative agreement with SRI International to provide formulation development, preclinical development, and...

QBIO : 1.7000 (unch)
The Global Cancer Therapy Market is set to Grow on the Wide use of Chemotherapy

Cancer is one of the leading causes of morbidity and mortality globally. In 2015, cancer was the second leading cause of death worldwide, accounting for 8.8 million deaths. Within the next two decades,...

QBIO : 1.7000 (unch)
EXAS : 68.31 (+0.68%)
MRK : 76.48 (-3.20%)
GILD : 65.57 (-2.64%)
PFE : 43.80 (-1.73%)
BMY : 52.12 (-2.83%)
NextGen Skeletal Cancer Drug Therapies Aim at Combating the Rising Incidence Rate of Global Cancer

Metastatic bone disease has proven to be more than agonizing for patients, especially when they discover that their cancer has reached an advanced stage, thereby diminishing their chance of survival and...

QBIO : 1.7000 (unch)
ASNS : 3.74 (-4.83%)
NVAX : 2.41 (+4.78%)
ABBV : 85.61 (-2.39%)
GE : 7.10 (-1.39%)
Q BioMed Inc Announces Acquisition of Cancer Pain Drug Metastron™ from GE Healthcare

NEW YORK , November 28, 2018 /PRNewswire/ --

QBIO : 1.7000 (unch)
Q BioMed Takes the Stage in the Expanded Access Debate at European Early and Managed Access Program Conference

NEW YORK , October 26, 2018 /PRNewswire/ --

QBIO : 1.7000 (unch)
Q BioMed Provides Important Update on QBM001 Developmental Drug Targeting a Non-Verbal and Minimally Verbal Patient Subset on the Autism Spectrum

NEW YORK , October 9, 2018 /PRNewswire/ --

QBIO : 1.7000 (unch)
Q Biomed Inc. Announces Dr. Rajendra Apte Joins Advisory Board

NEW YORK , Sept. 17, 2018 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotechnology acceleration development company, is pleased to announce that Rajendra Apte , MD, PhD has...

QBIO : 1.7000 (unch)
Q Biomed Inc. Announces Dr. Rajendra Apte Joins Advisory Board

Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotechnology acceleration development company, is pleased to announce that Rajendra Apte, MD, PhD has joined its Advisory Board contributing his extensive...

QBIO : 1.7000 (unch)
Q Biomed Inc. to Present at the Microcap Conference Taking Place April 9-10 at the Essex House in New York City

NEW YORK , April 5, 2018 /PRNewswire/ --

QBIO : 1.7000 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More Share

Trade QBIO with:

Key Turning Points

2nd Resistance Point 1.7667
1st Resistance Point 1.7333
Last Price 1.7000
1st Support Level 1.6833
2nd Support Level 1.6667

See More

52-Week High 4.6000
Fibonacci 61.8% 3.2057
Fibonacci 50% 2.7750
Fibonacci 38.2% 2.3443
Last Price 1.7000
52-Week Low 0.9500

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar